Healthy subjects
Conditions
Interventions
Group 1: nicotine before the experiment on day 1, 1mg (1 burst of spray), oral administration by spray
cayenne pepper spray before the experiment on day 2, 1 burst of spray.
We use a two day context-dependent cue conditioning paradigm. The context is a virtual room that subjects see on a screen. The c
Sponsors
Institut für Systemische Neurowissenschaften
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: healthy, non-smoker, 18-40 years old, normal BMI
Exclusion criteria
Exclusion criteria: 1. past or present illnesses of the - Brain or mind (incl. anxiety disorders, depression, schizophrenia, alcohol, drug or medication dependence, neurological disorders other than occasional headaches), - Heart or circulatory system (incl. hypertension), - blood, - lung, - liver, - kidneys, - thyroid gland, - Eyes (including glaucoma, color blindness, and myopia greater than -5 diopters), - skin, - gastrointestinal tract, - metabolism. It does not matter whether the disease is treated or untreated, was long or short term, or dates back a long time. This does not include former childhood illnesses and former harmless illnesses such as common gastrointestinal infections, stress headaches, colds, etc. 2. cancer. 3. hypersensitivity to nicotine. 4. current medication and medication in a period of 2 months before treatment. Only over-the-counter medications are excluded if their intake dates back more than 1 week before participation in the study. 5. other serious health problems or current severe mental or physical stress. 6. having metallic objects in or on the body that cannot be removed. 7. cigarette consumption of less than 1 cigarette in lifetime ("never-smoker").
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Group 1: The primary outcome measurement is the mean differential CS-response measured as US expectancy in the last block (8 trials) during ACQ (acquisition) compared to group 2 & 3 [(CS+ - CS-)ACQ,Block3,Group1<(CS+ - CS-)ACQ,Block3,Groups2&3]. Group 2: The primary outcome measurement is the mean differential CS-response measured as US expectancy in the last block (8 trials) during EXT (extinction) compared to group 3 [(CS+ - CS-)EXT,Block2,Group2<(CS+ - CS-)EXT,Block2,Groups3]. | — |
Secondary
| Measure | Time frame |
|---|---|
| Group1: Secondary outcome measures are the mean differential CS-responses measured as Fear ratings, skin conductance and hemodynamic brain responses (see ROIs) in the last block (8 trials) during ACQ compared to group 2 & 3 [(CS+ - CS-)ACQ,Block3,Group1<(CS+ - CS-)ACQ,Block3,Groups2&3]. Group2: Secondary outcome measures are the mean differential CS-responses measured as Fear ratings, skin conductance and hemodynamic brain responses (see ROIs) in the last block (8 trials) during EXT compared to group 3 [(CS+ - CS-)EXT,Block2,Group2<(CS+ - CS-)EXT,Block2,Groups3]. | — |
Countries
Germany
Contacts
Public ContactMadeleine Müller
Institut für Systemische Neurowissenschaften
Outcome results
None listed